Denosumab and romosozumab do not increase the risk of cardiovascular events in patients with primary osteoporosis:​ a reanalysis of the meta-analysis

Affiliations

¹The Department of Orthopaedic Surgery, Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, Sichuan, China

²The Department of Orthopaedic Surgery, Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region, Chengdu, Sichuan, China

³Department of Orthopaedic Surgery, The Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China

⁴The Department of Orthopaedic Surgery, Hospital Traditional Chinese Medicine (TCM) Affiliated to Southwest Medial University, Luzhou, Sichuan, China

Keywords

Keywords: Denosumab; Romosozumab; Cardiovascular events; Primary osteoporosis; Meta-analysis

Links

History

Received: 2020-01-20

Revised: 2020-02-11

Accepted: 2020-02-11

Online: 2020-04-2

Cited Works (1)

Year	Entry
2020	Lv F, Cai X, Yang W, Gao L, Chen L, Wu J, Ji L. Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: systematic review and meta-analysis. Bone. January 2020;130:115121.